Martineau Jérôme, Walz Solange N, Scampa Matteo, Giordano Salvatore, Kalbermatten Daniel F, Oranges Carlo M
Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.
Department of General and Plastic Surgery, Turku University Hospital, University of Turku, 20014 Turku, Finland.
J Clin Med. 2023 Mar 4;12(5):2045. doi: 10.3390/jcm12052045.
(1) Background: Spiradenocarcinoma is an extremely rare malignant adnexal tumor and there are only few studies on survival outcomes. Our aim was to perform an analysis of the demographic and pathological characteristics, treatment patterns, and survival outcomes of patients affected by spiradenocarcinoma. (2) Methods: The Surveillance, Epidemiology, and End Results program database of the National Cancer Institute was searched for all cases of spiradenocarcinoma diagnosed between 2000 and 2019. This database is considered representative of the US population. Demographic, pathological, and treatment variables were retrieved. Overall and disease-specific survival were computed according to the different variables. (3) Results: 90 cases of spiradenocarcinoma (47 females, 43 males) were identified. Mean age at diagnosis was 62.8 years. Regional and distant disease at diagnosis were rare, occurring in 2.2% and 3.3% of cases, respectively. Surgery alone was the most frequent treatment (87.8%), followed by a combination of surgery and radiotherapy (3.3%) and radiation therapy only (1.1%). Five-year overall survival was 76.2% and five-year disease-specific survival was 95.7%. (4) Conclusions: Spiradenocarcinoma equally affects males and females. Regional and distant invasion rates are low. Disease-specific mortality is low and is probably overestimated in the literature. Surgical excision remains the main form of treatment.
(1) 背景：汗腺癌是一种极其罕见的恶性附属器肿瘤，关于其生存结局的研究很少。我们的目的是分析汗腺癌患者的人口统计学和病理特征、治疗模式及生存结局。(2) 方法：在国家癌症研究所的监测、流行病学和最终结果计划数据库中检索2000年至2019年期间诊断的所有汗腺癌病例。该数据库被认为代表了美国人群。检索人口统计学、病理和治疗变量。根据不同变量计算总生存率和疾病特异性生存率。(3) 结果：共识别出90例汗腺癌病例（47例女性，43例男性）。诊断时的平均年龄为62.8岁。诊断时出现区域和远处疾病的情况罕见，分别占病例的2.2%和3.3%。单纯手术是最常见的治疗方式（87.8%），其次是手术与放疗联合（3.3%）以及仅放疗（1.1%）。五年总生存率为76.2%，五年疾病特异性生存率为95.7%。(4) 结论：汗腺癌对男性和女性的影响相同。区域和远处侵袭率较低。疾病特异性死亡率较低，可能在文献中被高估。手术切除仍然是主要的治疗方式。
